Blood Cancer Journal (Jul 2023)
Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia
- P. J. Hengeveld,
- J. Schilperoord-Vermeulen,
- M. Y. van der Klift,
- J. M. N. Dubois,
- P. M. Kolijn,
- F. G. Kavelaars,
- M. Rijken,
- J. A. Dobber,
- K. Nasserinejad,
- S. Kersting,
- P. E. Westerweel,
- A. P. Kater,
- A. W. Langerak,
- M-D. Levin
Affiliations
- P. J. Hengeveld
- Department of Internal Medicine, Albert Schweitzer Hospital
- J. Schilperoord-Vermeulen
- Department of Immunology, Erasmus MC
- M. Y. van der Klift
- Department of Immunology, Erasmus MC
- J. M. N. Dubois
- Department of Hematology and Experimental Immunology, Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam
- P. M. Kolijn
- Department of Immunology, Erasmus MC
- F. G. Kavelaars
- Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam
- M. Rijken
- Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam
- J. A. Dobber
- Department of Hematology and Experimental Immunology, Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam
- K. Nasserinejad
- HOVON Data Center, Department of Hematology, Erasmus MC Cancer Institute
- S. Kersting
- Department of Hematology, Haga Hospital
- P. E. Westerweel
- Department of Internal Medicine, Albert Schweitzer Hospital
- A. P. Kater
- Department of Hematology and Experimental Immunology, Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam
- A. W. Langerak
- Department of Immunology, Erasmus MC
- M-D. Levin
- Department of Internal Medicine, Albert Schweitzer Hospital
- DOI
- https://doi.org/10.1038/s41408-023-00870-2
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 4
Abstract
No abstracts available.
